Lung; Disease, Interstitial, With Fibrosis Clinical Trial
Official title:
Randomized Controlled Trial of Partitioned Aerobic Exercise Training of Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe as much allowing each leg a better workout. Our groundwork suggests it may work in patients with IPF. This study will help decide whether one-legged exercise training is better at improving a patient's exercise endurance compared to the usual way of exercising with both legs at the same time.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | October 31, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - confirmed idiopathic pulmonary fibrosis - Clinically stable - enrolled in pulmonary rehabilitation Exclusion Criteria: - co-morbidities that might impair their ability to safely complete a pulmonary rehabilitation program - complete a pulmonary rehabilitation program within the previous 6 months - experienced an exacerbation less than six weeks before participation |
Country | Name | City | State |
---|---|---|---|
Canada | West Park Healthcare Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
West Park Healthcare Centre |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cycle exercise endurance time | tolerance (time) of a constant power high intensity cycle endurance test | Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation | |
Secondary | health-related quality of life | using the questionnaire 'A Tool to Assess Quality of life in IPF' [ATAQ-IPF] | Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01781793 -
Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease
|
N/A | |
Not yet recruiting |
NCT03192657 -
Basiliximab Treating Interstitial Pneumonia of CADM
|
Phase 2 | |
Active, not recruiting |
NCT03747627 -
BPF Genetics of ILD Study
|
||
Completed |
NCT06383819 -
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
|
Phase 3 | |
Recruiting |
NCT05318599 -
Deep Learning Diagnostic and Risk-stratification for IPF and COPD
|